Scholar Rock Holding (SRRK) Net Cash Flow (2017 - 2026)
Scholar Rock Holding's (SRRK) quarterly Net Cash Flow came in at $106.4 million in Q1 2026, up 366.19% year-on-year from $22.8 million in Q1 2025, and up 189.32% quarter-over-quarter from $36.8 million in Q4 2025.
Scholar Rock Holding (SRRK) Net Cash Flow (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Net Cash Flow history runs 10 years deep, the most recent figure standing at $106.4 million for Q1 2026.
- On a quarterly basis, Net Cash Flow rose 366.19% year-over-year to $106.4 million in Q1 2026; TTM through Mar 2026 was $293.4 million, a 538.46% increase from a year earlier, with the FY2025 full-year figure at $147.1 million, up 93.43% from the prior year.
- Net Cash Flow improved to $106.4 million in Q1 2026 per SRRK's latest filing, from $36.8 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $205.6 million in Q2 2022 and bottomed at -$172.7 million in Q3 2022.
- The 5-year median for Net Cash Flow is $1.4 million (2024), against an average of $12.8 million.
- Across the five-year window, Net Cash Flow tumbled 8912.8% in 2022 and soared 976.74% in 2025, its largest moves.
- Year by year, Net Cash Flow stood at -$29.8 million in 2022, then jumped by 214.27% to $34.1 million in 2023, then surged by 198.04% to $101.5 million in 2024, then plunged by 63.78% to $36.8 million in 2025, then jumped by 189.32% to $106.4 million in 2026.
- Per Business Quant, the three latest SRRK Net Cash Flow figures stand at $106.4 million (Q1 2026), $36.8 million (Q4 2025), and $135.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 10.56 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 224.46 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.34 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 457.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -152.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 57.19 Mn |
| 10 | Scholar Rock Holding | 6.30 Bn | 6.30 Bn | - | 106.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 106.35 Mn |
| Mar 31, 2026 | 106.35 Mn |
| Dec 31, 2025 | 36.76 Mn |
| Dec 31, 2025 | 36.76 Mn |
| Sep 30, 2025 | 135.25 Mn |
| Sep 30, 2025 | 135.25 Mn |
| Jun 30, 2025 | 15.00 Mn |
| Jun 30, 2025 | 15.00 Mn |
| Mar 31, 2025 | -39.95 Mn |
| Mar 31, 2025 | -39.95 Mn |
| Dec 31, 2024 | 101.49 Mn |
| Dec 31, 2024 | 101.49 Mn |
| Sep 30, 2024 | -16.98 Mn |
| Sep 30, 2024 | -16.98 Mn |
| Jun 30, 2024 | 1.39 Mn |
| Jun 30, 2024 | 1.39 Mn |
| Mar 31, 2024 | -9.88 Mn |
| Mar 31, 2024 | -9.88 Mn |
| Dec 31, 2023 | 34.05 Mn |
| Dec 31, 2023 | 34.05 Mn |